Executive Chairman David Schlanger Sells 60,000 Shares of Progyny Inc (PGNY)
On February 2, 2024, Executive Chairman David Schlanger sold 60,000 shares of Progyny Inc (NASDAQ:PGNY), as reported in a recent SEC filing. The transaction was executed with the shares priced at $38.6 each, resulting in a total sale amount of $2,316,000.
Progyny Inc is a company that specializes in fertility and family building benefits solutions in the United States. It provides employers with fertility benefits for their employees, which includes access to a network of fertility specialists, treatment financing, and comprehensive patient support services.
According to the data provided, the insider has been active in the market over the past year, selling a total of 1,158,715 shares and making no purchases. This latest transaction continues the trend of insider sales for the company.
The insider transaction history for Progyny Inc shows a pattern of insider selling, with 43 insider sells and no insider buys over the past year.
Shares of Progyny Inc were trading at $38.6 on the day of the insider's recent sale, giving the company a market capitalization of $3.725 billion. The price-earnings ratio stands at 74.69, which is above the industry median of 26.91 but below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 0.47, with a GF Value of $82.15, indicating that Progyny Inc is significantly undervalued according to GuruFocus's valuation model. The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
